X Chem Appoints Karen Lackey As CSO and David Hagerman As CFO
08/10/23, 2:27 PM
Location
Industry
science and engineering
health care
biotechnology
Position
chief financial officer
WALTHAM, Mass.–– X-Chem , the leading provider of innovative solutions in early-stage drug discovery, announced the addition of Karen Lackey as chief scientific officer and David Hagerman as chief financial officer to its global executive management team.
Company Info
Location
waltham, massachusetts, united states
Additional Info
X-Chem, Inc. is the leader in small molecule discovery science, providing pharmaceutical and biotech companies a complete, seamless solution for screening, hit validation and lead optimization. As pioneers of DNA-encoded chemical library (DEL) technology, the company leverages its market-leading DEL platform to discover novel small molecule leads against challenging, high-value therapeutic targets. X-Chem empowers partners to rapidly screen billions of diverse, drug-like compounds simultaneously and easily identify potent hits that exhibit desired selectivity and mode of action with attractive physicochemical properties. In-house, lead optimization services enable clients to progress their compounds directly for even higher quality outputs. Our expertise in medicinal chemistry, custom synthesis and scale-up process chemistry enables us to support all aspects of drug discovery, supporting lead optimization through candidate identification.